Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence - Wikidata - wikimedia - TriplyDB

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

http://www.wikidata.org/entity/Q37349067

about

Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease A Review of Daclatasvir Drug-Drug Interactions Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C Screening and surveillance for hepatocellular carcinoma: perspective of a new era?The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Daclatasvir: A Review in Chronic Hepatitis C.Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.New Therapies for Hepatitis C Virus Infection.Hepatitis C in a New Era: A Review of Current Therapies Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.Hepatitis C Virus and Liver Transplantation.Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis.Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients.DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease New perspectives for preventing hepatitis C virus liver graft infection.A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.SASLT guidelines: Update in treatment of Hepatitis C virus infection.Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort.Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study.National assessment of early hospitalization after liver transplantation: Risk factors and association with patient survival.Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions.Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.

P2860

Q26740319-70FC7BB8-F5BC-4073-97A5-EC77921AA4CC Q26746563-3386A5B4-8782-486C-9FA5-A20B7031382D Q26751452-B56836AA-DECA-4E91-AC33-A93D6507DA6E Q26752433-E7239E2D-F8A1-4328-835F-2783AF5AFD7B Q28068712-7F2884B5-6965-4380-B4E9-CB7881A5B653 Q28073100-BA6360EA-3DCB-4FE0-AF3E-2371D7EC6534 Q28076406-5D855E96-2D14-4CB9-81AB-264017A40A09 Q28076883-6C2A48EC-F903-4971-8205-F13578A7C06C Q28077287-DEA9ED9B-0DAB-43E4-B5E3-8B6597AA72C6 Q30235178-32570D0E-C73F-462A-9148-D30DE4D486FE Q30244651-50ADC09B-D6B5-4365-AC5E-3B34B809A095 Q30250096-650965C9-D88D-4FAF-B8EC-00C33E9C92FB Q30250322-861923CB-F9F2-4758-87FA-6532AD1F1FB0 Q30355190-DAB67102-7F9D-4DFB-8C42-CD757E7D72E6 Q30392100-04F10B7A-0B56-4EDF-A9F1-E85855E79FFF Q30399476-2783CB63-08CC-400E-9DA4-F0609AF4CFF0 Q31160142-1C0D9825-C1B1-4477-A414-6839849378C7 Q33557819-19C50783-0C1C-4573-B4CC-DF8008EFE7AA Q33560181-A49C0D3E-75CE-4732-B66D-55CD127162A5 Q33585021-358C7A75-D2EC-4373-B099-8B02F72E6615 Q33703634-DE23F9A4-C78F-4D23-9DF0-67C5B43B958D Q33717116-5FF0CAE0-43A8-4674-A0FB-5B3339247F51 Q33745372-3768102C-8768-46C5-80E7-100FFE9AAD6C Q36165389-FA637A0E-DDEA-43DD-BD3D-35C35BF59600 Q36229505-5B3E06B5-EF8D-45A5-9D06-35CAB09F005E Q36243096-139E96A9-1BDF-4FB3-BE5C-4A9AF2E4EF7C Q37015805-69D8974E-8EC1-40E4-BD70-811DCB5809ED Q37187994-F2DC9A40-82E1-483A-84CB-9B1A62D24710 Q37216507-3A7F7810-F4B1-4543-8FBA-A495462446BB Q37398996-E6395071-A3B7-4AA5-AA09-B6B919D11831 Q37563692-02908BE4-9E6E-4689-9731-108713228516 Q38384095-399A00B0-F9B7-48AE-A83D-018F17B08C07 Q38688657-31340C20-1D75-4D29-BE00-D21524B613F8 Q38735317-527BCA4D-E8E6-4CE9-A1CD-9AE7A26B3AC9 Q38763789-394467CC-6868-4143-9D77-7BB414C3A284 Q38859081-4D8949C8-CFD8-4B8E-B7EF-70116FF93DDB Q38859560-148F8DD4-98E9-4DB7-8E74-A9AE54928713 Q38893244-AEBA0EB7-EF52-4FF8-9221-35A13C4BE8EA Q38927205-ADF92AC7-15ED-4FEF-B574-2B669997A5A5 Q38972180-22A0D241-1911-4CFC-A6EC-FA3C9EB2834B

P2860

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

http://www.wikidata.org/entity/Q37349067

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 January 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Daclatasvir with sofosbuvir an ...... ver transplantation recurrence

@en

Daclatasvir with sofosbuvir an ...... er transplantation recurrence.

@nl

type

label

Daclatasvir with sofosbuvir an ...... ver transplantation recurrence

@en

Daclatasvir with sofosbuvir an ...... er transplantation recurrence.

@nl

prefLabel

Daclatasvir with sofosbuvir an ...... ver transplantation recurrence

@en

Daclatasvir with sofosbuvir an ...... er transplantation recurrence.

@nl

P1433

Q37349067-9838E04E-C307-47CF-9988-C075C7E1C76A

P1476

Q37349067-105731D3-33AA-4B71-A66B-F7ED474AF866

P2093

Q37349067-0BFA0F34-F5F4-4C21-A9BA-7B13E25B6A97

Q37349067-0E300EAE-5D28-4BE3-B059-C09B34996A64

Q37349067-1E6641C8-DC5D-458C-923F-2324223041DB

Q37349067-2ADBCAA6-EDD6-4CBF-BA97-861CF2BB82C6

Q37349067-81DC784B-87B8-4D61-A92E-E363A856830E

Q37349067-A5A7A971-97F5-4D9C-826D-1C84FDBD5B8D

Q37349067-BCDE54ED-29FD-44AE-87D7-F12C45606D15

Q37349067-CB5BEBCD-E01D-4FB5-9ED6-2E5FDF089973

Q37349067-D72D5516-397D-4D04-B679-4214B348D608

P2860

Q37349067-0317EA7D-62CE-46A0-AF04-4225C602E892

Q37349067-16C36C7A-09FF-42EE-AB4D-2E94923216AC

Q37349067-1ADE754E-8E54-4A52-B5B9-85A14F23A1F1

Q37349067-1EC545DB-12EB-4CF5-B0AA-81DC34E6A106

Q37349067-272F66AC-E989-4987-8048-0810345EC866

Q37349067-31B4EF95-7E8D-404C-9C36-B04319006FD6

Q37349067-31EC9907-8C70-4730-9404-830D834D7B60

Q37349067-355176A8-C2BE-4318-8506-8BC2D02FF7A9

Q37349067-5E12BFA1-83D2-46F6-8797-09A50BC81BD1

Q37349067-617334D4-513F-4DC9-BC39-ED9D476363A0

P304

Q37349067-1F39308E-2C7E-42CB-997F-A53E834AE79E

P31

Q37349067-27AB2F38-05A1-40B6-87EF-03DC66672B68

P356

Q37349067-BA3E0655-31E4-42EC-ADEF-3133D8773A7C

P407

Q37349067-989F4654-D915-479D-977B-8D2C4171754B

P433

Q37349067-B75DF316-E562-42FB-A18D-2655CCE4F231

P478

Q37349067-D5E5F427-8AA5-41E6-9F3E-218CCCC3FE55

P50

Q37349067-16FFF6ED-59A7-4DDF-8D61-CA7F6093F5DE

P577

Q37349067-2563A6B9-BBF7-4AA3-A849-02A288E3BE0D

P698

Q37349067-85AA3886-476F-45F9-93F4-D0138151EE90

P921

Q37349067-4FCFF4D2-0A29-438A-9E00-B78795E24C26

Q37349067-827CC266-1E46-4740-9DE9-3F6ADB4EDEBF

Q37349067-F98E9F8B-BEDE-4664-AC9C-8DF7B0956FE6

P932

Q37349067-7971D132-065A-4EA1-9E36-0D732AB772ED

P356

P1433

P1476

Daclatasvir with sofosbuvir an ...... ver transplantation recurrence

@en

P2093

Charles Landis

http://www.w3.org/2001/XMLSchema#string

Eric A Hughes

http://www.w3.org/2001/XMLSchema#string

Eugene R Schiff

http://www.w3.org/2001/XMLSchema#string

Eugene S Swenson

http://www.w3.org/2001/XMLSchema#string

Fiona McPhee

http://www.w3.org/2001/XMLSchema#string

John M Vierling

http://www.w3.org/2001/XMLSchema#string

Robert J Fontana

http://www.w3.org/2001/XMLSchema#string

Rong Yang

http://www.w3.org/2001/XMLSchema#string

Stephanie Noviello

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

The global burden of hepatitis C

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

OPTN/SRTR 2012 Annual Data Report: liver.

Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.

Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.

P304

1493-1505

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.28446

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26754432

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation

liver cirrhosis

P932

5069651

http://www.w3.org/2001/XMLSchema#string